Effects of Atorvastatin on Kidney Outcomes and Cardiovascular Disease in Patients With Diabetes: An Analysis From the Collaborative Atorvastatin Diabetes Study (CARDS)
Helen M. Colhoun(Cleveland Clinic), John Fuller(University of Verona), David A. DeMicco(Pfizer (United States)), Valentine Charlton-Menys(Manchester Royal Infirmary), G. A. Hitman, Paul N. Durrington, H. A. W. Neil(University of Oxford), D. J. Betteridge, Shona Livingstone(University College London)
Cited by 253
Related Papers
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
|The Lancet|2004|3.8k
ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
|European Heart Journal|2011|3.5k
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
|New England Journal of Medicine|2023|2.6k
Vascular Risk Factors and Diabetic Neuropathy
|New England Journal of Medicine|2005|1.3k